ZA915727B - Quinuclidine derivatives - Google Patents

Quinuclidine derivatives

Info

Publication number
ZA915727B
ZA915727B ZA915727A ZA915727A ZA915727B ZA 915727 B ZA915727 B ZA 915727B ZA 915727 A ZA915727 A ZA 915727A ZA 915727 A ZA915727 A ZA 915727A ZA 915727 B ZA915727 B ZA 915727B
Authority
ZA
South Africa
Prior art keywords
quinuclidine derivatives
quinuclidine
derivatives
migraine
antagonists
Prior art date
Application number
ZA915727A
Other languages
English (en)
Inventor
John A Lowe Iii
A Lowe John Iii
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ZA915727B publication Critical patent/ZA915727B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Soft Magnetic Materials (AREA)
  • Paper (AREA)
  • Control Of Electric Motors In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA915727A 1990-07-23 1991-07-22 Quinuclidine derivatives ZA915727B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55744290A 1990-07-23 1990-07-23

Publications (1)

Publication Number Publication Date
ZA915727B true ZA915727B (en) 1993-02-24

Family

ID=24225412

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA915727A ZA915727B (en) 1990-07-23 1991-07-22 Quinuclidine derivatives

Country Status (25)

Country Link
US (5) US5422354A (fr)
EP (1) EP0540526B1 (fr)
JP (1) JP2514137B2 (fr)
CN (1) CN1058405A (fr)
AT (1) ATE116317T1 (fr)
AU (1) AU660416B2 (fr)
BR (1) BR9106665A (fr)
CA (1) CA2086434C (fr)
DE (1) DE69106365T2 (fr)
DK (1) DK0540526T3 (fr)
ES (1) ES2065691T3 (fr)
FI (1) FI114473B (fr)
GR (1) GR3015144T3 (fr)
HU (1) HUT62584A (fr)
IE (1) IE65000B1 (fr)
IL (1) IL98860A (fr)
MX (1) MX9100308A (fr)
MY (1) MY107157A (fr)
NO (1) NO302172B1 (fr)
NZ (1) NZ239063A (fr)
PL (1) PL167568B1 (fr)
PT (1) PT98393B (fr)
WO (1) WO1992001688A1 (fr)
YU (1) YU128091A (fr)
ZA (1) ZA915727B (fr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2065691T3 (es) * 1990-07-23 1995-02-16 Pfizer Derivados de quinuclidina.
US5716965A (en) * 1991-05-22 1998-02-10 Pfizer Inc. Substituted 3-aminoquinuclidines
ATE142199T1 (de) * 1991-06-20 1996-09-15 Pfizer Fluoralkoxybenzylaminoderivate stickstoffhaltiger heterocyclen
TW202432B (fr) * 1991-06-21 1993-03-21 Pfizer
WO1993006099A1 (fr) * 1991-09-16 1993-04-01 Pfizer Inc. Heterocycles tricycliques fusionnes, contenant de l'azote, utilises comme antagonistes de recepteur de substance p
DK0613458T3 (da) * 1991-11-12 1998-02-09 Pfizer Acykliske ethylendiaminderivater som substans P receptorantagonister
EP0641328B1 (fr) * 1992-05-18 2001-11-21 Pfizer Inc. Derives aza-bicycliques en pont utiles comme antagonistes de la substance p
WO1994003445A1 (fr) * 1992-08-04 1994-02-17 Pfizer Inc. Derives de la piperidine 3-benzylamino-2-phenyle en tant qu'antagonistes des recepteurs de la substance p
ES2164072T3 (es) * 1992-08-19 2002-02-16 Pfizer Heterociclos no aromaticos que contienen nitrogeno sustituidos con bencilamino.
CA2150123C (fr) * 1992-12-10 2004-12-07 Harry R. Howard Derives de substitution aminomethylene d'heterocycles non aromatiques
US5830854A (en) * 1992-12-14 1998-11-03 Merck Sharp & Dohme, Limited Method of treating cystic fibrosis using a tachykinin receptor antagonist
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0655246A1 (fr) * 1993-11-30 1995-05-31 Pfizer Inc. Antagonistes de la substance P pour le traitement des maladies causées par Helicobacter Pylori ou d'autres bacteries spirales, ureare-positives, gram-négatives
FR2725900B1 (fr) * 1994-10-21 1997-07-18 Sanofi Sa Utilisation d'antagonistes des recepteurs nk1 pour la preparation de medicaments a action cardioregulatrice
IL116249A (en) * 1994-12-12 2003-07-06 Pfizer Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
GB9502582D0 (en) * 1995-02-10 1995-03-29 Smithkline Beecham Plc Novel process
GB9510459D0 (en) * 1995-05-24 1995-07-19 Zeneca Ltd Bicyclic amines
EP0901490B1 (fr) * 1996-05-13 2004-04-07 Syngenta Limited Amines bicycliques utilisees comme insecticides
AU3784997A (en) * 1996-08-09 1998-03-06 Eisai Co. Ltd. Benzopiperidine derivatives
GB9623944D0 (en) * 1996-11-15 1997-01-08 Zeneca Ltd Bicyclic amine derivatives
GB9624114D0 (en) * 1996-11-20 1997-01-08 Zeneca Ltd Pesticidal bicyclic amine derivatives
CN1245499A (zh) 1996-11-26 2000-02-23 曾尼卡有限公司 8－氮杂双环[3.2.1]辛烷,8－氮杂双环[3.2.1]辛－6－烯,9－氮杂双环[3.3.1]壬烷,9－氮杂－3－氧双环[3.3.1]壬烷和9－氮杂－3－硫双环[3,3,1]壬烷衍生物,它们的制备以及作为杀虫剂的应用
GB9624611D0 (en) * 1996-11-26 1997-01-15 Zeneca Ltd Bicyclic amine compounds
EP1220854A2 (fr) 1999-09-27 2002-07-10 University Georgetown Nouveaux analogues de tropane
JP2001172178A (ja) * 1999-10-25 2001-06-26 Pfizer Prod Inc 偏頭痛治療用のｎｋ−１レセプターアンタゴニスト及びエレトリプタン
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
CA2389306C (fr) 1999-11-03 2010-03-30 Albany Molecular Research, Inc. Tetrahydroisoquinolines a substitution aryle et heteroaryle et utilisation de ces composes pour bloquer le recaptage de norepinephrine, de dopamine et de serotonine
AU7334901A (en) 2000-07-11 2002-01-21 Du Pont Pharm Co Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (fr) * 2000-09-28 2003-03-26 Pfizer Products Inc. Composition pour le traitement de la dépression et de l'anxieté contenant un antagoniste du recepteur NK-3 et un antagoniste du récepteur NK-1
WO2006020049A2 (fr) 2004-07-15 2006-02-23 Amr Technology, Inc. Tetrahydroisoquinolines a substitution aryle et heteroaryle et leur utilisation pour bloquer le recaptage de la norepinephrine, la dopamine et la serotonine
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
CN101495184A (zh) 2005-07-15 2009-07-29 Amr科技公司 芳基和杂芳基取代的四氢苯并氮杂及其在阻断去甲肾上腺素多巴胺和血清素的重摄取中的应用
JP4879988B2 (ja) 2005-09-29 2012-02-22 メルク・シャープ・エンド・ドーム・コーポレイション メラノコルチン−４受容体モジュレーターとしてのアシル化スピロピペリジン誘導体
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2770486C (fr) 2006-09-22 2014-07-15 Merck Sharp & Dohme Corp. Utilisation de la platencine et de la platensimycine en tant qu'inhibiteurs de la synthese des acides gras pour traiter l'obesite, lediabete et le cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
US8071623B2 (en) 2007-01-10 2011-12-06 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors
WO2008090117A1 (fr) 2007-01-24 2008-07-31 Glaxo Group Limited Nouvelles compositions pharmaceutiques
AU2008233662B2 (en) 2007-04-02 2012-08-23 Msd K.K. Indoledione derivative
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
JP2011515343A (ja) 2008-03-03 2011-05-19 タイガー ファーマテック チロシンキナーゼ阻害薬
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
WO2010114780A1 (fr) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibiteurs de l'activité akt
DK2429296T3 (en) 2009-05-12 2018-03-12 Albany Molecular Res Inc 7 - ([1,2,4,] TRIAZOLO [1,5, -A] PYRIDIN-6-YL) -4- (3,4-DICHLORPHENYL) -1,2,3,4- TETRAHYDROISOQUINOLINE AND USE thereof
ES2446971T3 (es) 2009-05-12 2014-03-11 Albany Molecular Research, Inc. Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
BR112012008849A2 (pt) 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
EP2584903B1 (fr) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
JP2013537423A (ja) 2010-08-17 2013-10-03 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2608669B1 (fr) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. Nouveaux dérivés de pyrazolo[1,5-a]pyrimidine utilisés comme inhibiteurs de mtor
WO2012030685A2 (fr) 2010-09-01 2012-03-08 Schering Corporation Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
WO2012036997A1 (fr) 2010-09-16 2012-03-22 Schering Corporation Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
EP3766975A1 (fr) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina)
WO2012087772A1 (fr) 2010-12-21 2012-06-28 Schering Corporation Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
WO2012143879A1 (fr) 2011-04-21 2012-10-26 Piramal Healthcare Limited Forme cristalline d'un sel d'un dérivé de morpholinosulfonylindole et son procédé de préparation
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
EP2791135B8 (fr) * 2011-12-12 2018-07-18 KemPharm Consulting Inc. Dérivés d'anabasine ciblant les récepteurs nicotiniques de l'acétylcholine
EP3453762B1 (fr) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Compositions d'acide nucléique interférent court (sina)
WO2014052563A2 (fr) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Nouveaux composés inhibiteurs de erk
CA2891122C (fr) 2012-11-14 2021-07-20 The Johns Hopkins University Methodes et compositions pour le traitement de la schizophrenie
PT2925888T (pt) 2012-11-28 2017-12-13 Merck Sharp & Dohme Composições e métodos para tratamento do cancro
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
WO2014120748A1 (fr) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
EP3041938A1 (fr) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Polynucléotides circulaires
ES2809703T3 (es) 2015-09-04 2021-03-05 Janssen Pharmaceutica Nv Compuestos terapéuticos para el dolor y síntesis de los mismos
WO2018071283A1 (fr) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Inhibiteurs de kdm5
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2020033284A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2455949A (en) * 1947-06-02 1948-12-14 Parke Davis & Co Dialkylaminoalkyl benzahydryl ethers and salts thereof
US3560510A (en) * 1969-03-05 1971-02-02 Aldrich Chem Co Inc 2-benzhydrylquinuclidines
GB1527489A (en) * 1976-08-05 1978-10-04 Andreu Sa Dr Amine compound
US4246201A (en) * 1979-06-11 1981-01-20 Alfa Farmaceutici, S.P.A. Substituted N-(3-phenylthiopropyl)-3,3-diphenyl-propylamines possessing pharmacological activity
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
WO1991009844A1 (fr) * 1990-01-04 1991-07-11 Pfizer Inc. Antagonistes de la substance p
US5451586A (en) * 1990-06-01 1995-09-19 Pfizer Inc. 3-amino-2-aryl quinuclidines
ES2065691T3 (es) * 1990-07-23 1995-02-16 Pfizer Derivados de quinuclidina.

Also Published As

Publication number Publication date
YU128091A (sh) 1994-01-20
PT98393A (pt) 1992-05-29
PT98393B (pt) 1999-01-29
DK0540526T3 (da) 1995-04-18
FI114473B (fi) 2004-10-29
DE69106365T2 (de) 1995-05-04
NO930222L (no) 1993-01-22
US5641786A (en) 1997-06-24
US5422354A (en) 1995-06-06
JPH05507687A (ja) 1993-11-04
PL167568B1 (pl) 1995-09-30
MY107157A (en) 1995-09-30
WO1992001688A1 (fr) 1992-02-06
CA2086434C (fr) 1998-09-22
CN1058405A (zh) 1992-02-05
US5854256A (en) 1998-12-29
US5821248A (en) 1998-10-13
IE65000B1 (en) 1995-10-04
CA2086434A1 (fr) 1992-01-24
IE912560A1 (en) 1992-01-29
NO930222D0 (no) 1993-01-22
FI930262A0 (fi) 1993-01-22
FI930262A (fi) 1993-01-22
HU9300188D0 (en) 1993-04-28
NZ239063A (en) 1995-09-26
EP0540526A1 (fr) 1993-05-12
GR3015144T3 (en) 1995-05-31
AU7894891A (en) 1992-02-18
DE69106365D1 (de) 1995-02-09
JP2514137B2 (ja) 1996-07-10
AU660416B2 (en) 1995-06-29
EP0540526B1 (fr) 1994-12-28
US5698568A (en) 1997-12-16
BR9106665A (pt) 1993-06-08
IL98860A (en) 1995-11-27
ATE116317T1 (de) 1995-01-15
HUT62584A (en) 1993-05-28
MX9100308A (es) 1992-02-28
IL98860A0 (en) 1992-07-15
ES2065691T3 (es) 1995-02-16
NO302172B1 (no) 1998-02-02

Similar Documents

Publication Publication Date Title
GR3015144T3 (en) Quinuclidine derivatives.
EG20218A (en) Process for preparing of substituted 3 aminoquinuclidines
HU9602409D0 (en) Prodrugs of morpholine tachykinin receptor antagonists
BG104561A (en) Aryl fused azapolycyclic compounds
GR3026231T3 (en) 3-aminopiperidine derivatives and related nitrogen containing heterocycles.
CA2102179A1 (fr) Derives quinuclidine
YU64400A (sh) Aril fuzirana azapoliciklična jedinjenja
YU140491A (sh) 6-supstituisani-tetrahidrobenz(c,d) indoli